Archive for the ‘China Health Resource Inc. CHRI’ Category

China Health Resource, Inc. (CHRI.OB) Firmly Roots itself within Booming Traditional Chinese Herbal Medicine Market

Tuesday, March 4th, 2008

The medicinal use of Chinese Herbal Medicine (CHM) dates back more than 3,000 years; today it remains an integral part of Traditional Chinese and East Asian Medicine, accounting for 90% of China’s medicinal treatments. Each year about 1.28 billion patients seek various forms of CHM, including acupuncture, massage and Qigong therapy. As herbal medicine continues to grow in the East, its reach influences Western countries, and has become part of a multibillion-dollar market.

China Health Resource, Inc. (OTCBB: CHRI) devotes its operations to the development of traditional Chinese herbal medicine, focusing on a unique Chinese herbal medicine used to treat pain and various afflictions. Dahurian Angelica Root (DAR) is believed do cure diseases such as high-blood pressure, cancer and more.

The description and classification of each medicinal herb is dire for the continuation of CHM. An herbal pharmacopoeia details medicinal substances, describing physical characteristics and applications. China’s pharmacopoeia contains more than 10,000 entries, while the U.S. covers roughly 400. To further its own development and studies of DAR, China Health Resource has established a relationship with Chengdu University of Traditional Chinese Medicine and the Sichuan Provincial Chinese Medicine Research Institute.

China Health Resource cites that DAR’s applications are expanding from the medical field, and are now used for cosmetics and chemistry purposes. According to the company, the international market share of herbal medicine is up to 27 billion U.S. dollars each year, and continues to grow. China Health Resource is focused on expanding the global market of DAR, and making a dominant presence in the industry.

Let us hear your thoughts: China Health Resource, Inc. Message Board

Five Reasons Why China Health Resources Inc. (CHRI.OB) Stock is Set to Soar

Thursday, February 21st, 2008

 This China based traditional Medicine Company is an excellent value to Investors. A number of recent events have strengthened the company’s market position, making this quite a safe investment to consider with very nice upside potential. There are a number of reasons why now is the time to invest in this company, but five stand out as key indicators of its future prospect of success.

First is Global demand. Right now Alternative medicine is quickly gaining popularity and market share around the world. It represents a $30 billion dollar market in the US and Europe alone. This has to do with many consumers in these countries leaning toward green living. In fact, 80% of the world population is said to use some form of Herbal Medicine. So clearly, the potential market for the company’s product is huge.

Their stock right now is being priced at an extremely low multiple due to current market conditions. The price multiplier should be much higher given the recent GAP certification that they received. This leads to the next point.
 GAP is essentially FDA approval for China and the EU so this is clearly huge. Similar company’s in the US receiving FDA approval trade at sometimes 40 times earnings overnight after the announcement. In fact, this is truly the Golden Egg of Alternative medicine companies. It gives them credibility with the government and consumers’ peace of mind knowing their product is safe. This also means the company can export to the US.

In the world of Alternative Medicine, the products that succeed are the ones that are the most easily marketed. That is why the company has chosen to put its eggs in one basket and focus on DAR, known for its many healing qualities including headaches, pain, blood pressure and many other ailments. This simplifies the complexities usually associated with promoting traditional medicine and allows the customer and the company to focus on one Branded drug. This has proven successful in India with the Ayurvedic system of medicine now representing a $1 billion dollar business.

Last week shares jumped almost 64% with the News that the company had added a successful research professor familiar with DAR to its team. Jia Minru comes from the Chinese Medicine University. He has headed a number of advanced studies in DAR and CHAUN as well as implementation of GAP standards. He brings over 40 years of experience to the company, a tremendous asset and great competitive edge over their competitors.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resources Inc. (CHRI.OB) Sees Single Herb Focus as a Sure Way to Success

Wednesday, February 20th, 2008

When one goes to Vitamin Stores these days, they see literally hundreds of different Herbal Medicines with 100s of different ingredients. This is all very confusing for the customer as they try to understand each ingredient. Successful herbal supplements marketed around a single Herb include Aspirin, Digitalis, Quinine and Ayurvedic. This Branding helps the customer recognize the drug under its Branded name, eliminating the difficulties of promoting traditional medicine as many are quite complex. It also makes the promotion much easier as the company focuses on only one Herb.

Ayurvedic is an example of Single Herb Branding. It is so successful that it now represents a $1 billion dollar market in India alone. One company that produces Ayurvedic in India generates $45 million in yearly revenue. DAR, a traditional Chinese medicine that China Health Resources Inc. focuses on, is growing in popularity exponentially. Consumer awareness of the dug and its abilities also continues to grow. They have decided to focus solely on DAR, as part of a focused marketing campaign much like the one used by Indian companies for Ayurvedic.

It is easy to see the benefits of single herb focus in complex traditional medicine. Not only is the company able to target scarce marketing dollars in one direction, it can also strive to integrate at every level of the Drugs creation from the fields to the research facilities. They have done this and stand as a prime example of a Single Herb company. Marketing Herbs around a single product has many successful examples and they intend to make DAR the next successful one.

Let us hear your thoughts: China Health Resource, Inc. Message Board

Why China Health Resources Inc. (CHRI.OB) is Currently Undervalued

Wednesday, February 20th, 2008

Last year was a rough year for this Herbal Medicine Company focused on DAR, a traditional Chinese medicine known to cure many ailments, as they reported a loss of .01 cents per share. This however was a rough year for most agricultural firms within China as the year saw tremendous flooding that destroyed many crops. The market is still pricing this past information into this stock when this year has been quite good for the company.

They recently received the coveted Chinese equivalent to FDA approval, “GAP”. This is huge for the company and almost instantaneously adds franchise value to the firm as they can now export the product almost anywhere in the world. GAP is the same agriculture standard used by the EU. They also added a Research Scientist with over 40 years of experience giving them a tremendous competitive advantage over other firms in the DAR industry. This year the company has also grown operations with acquisitions and strategic partnerships, all of which one would think increases the shareholder value. However, the market seems to be failing at pricing this into the value of the company as it trades close to its 52 weeks lows.

A wise investor would see this as a tremendous value play as its Market Cap today is about $8 million. DAR is in its very early stages of growth, it has tremendous upside potential; in fact, one company alone competing in the Ayurvedic industry, an Herbal Medicine grown in India, generates sales of $45 million yearly. It is quite possible that DAR will become the next Ayurvedic. Because of the GAP approval, investors can be assured that they are not in the business of smoke and mirrors and that DAR from this company is the real deal produced at the highest standards. The market is not seeing this gem, making it a diamond in the rough for Investors looking for a value with huge upside potential.

China Health Resources Inc. and its subsidiaries focus on developing and commercializing Dahurian Angelica Root. They are located in the Suining, Sichuan province of China where 70% of China’s DAR output comes from. The company intends to build a total value chain at every step of the DAR Industry, from production to research. The company currently has 11,000-mu DAR field and has built a GAP research basement of 2,000 mu. They also have a number of research agreements with Chinese universities and professors providing a strong platform for R&D.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource Inc. (CHRI.OB) Sees Surge in Trading Activity in Light of Recent Business Activity

Tuesday, February 19th, 2008

This China based Agriculture Company recently announced the addition of a Chinese Herbal Medicine expert. Jia Minru a Medicinal expert joined the company’s team and brings over 40 years of experience to the company. He is a professor at the Chinese Medicine University. Mr. Minru is responsible for a number of advanced studies Chuan DAR GAP. His addition will almost certainly give Suining Chuan a competitive advantage in the commercialization and scientific advancement of Dahurian Angelica Root and other medicinal herbs.

Shortly after the announcement, the trading volume surged above 1 million. The Volume average is around 300K, so this is a significant increase in trading activity. The 50-day moving average also began trending upwards toward the 100-day moving average indicating a possible trend reversal for the stock. When looked at in a Point and Figure Chart, a Three-box reversal pattern is showing. On a Candle chart volume is far stronger on upwards movement and weak on downward movements. All of these are excellent technical indications of a price reversal for China Health Resources.

China Health Resources Inc. and its subsidiaries are focused on developing and commercializing Dahurian Angelica Root. They are located in the Suining, Sichuan province of China where 70% of China’s DAR output comes from. The company intends to build a total value chain at every step of the DAR Industry, from production to research. The company currently has 11,000-mu DAR field and has built a GAP research basement of 2,000 mu, planting field of 11,000 mu. They also have a number of research agreements with Chinese universities and professors providing a strong platform for R&D.

Let us hear your thoughts: China Health Resource, Inc. Message Board

Herbal Medicine Company China Health Resources Inc. (CHRI.OB) Seeks to Capitalize on Economic Growth and Acceptance of Herbal Medicines

Tuesday, February 19th, 2008

Consumers are spending more and more every year on Alternative Medicines. In a recent study conducted by the World Health Organization, 80% of the world’s population uses some form of Herbal Medicine. Global Sentiment towards Herbal Medicine seems to be increasing as well. The biggest problem faced by the company is the marketing complexities associated with the promotion of traditional medicine systems.

The company has solved this problem by focusing on one type of Herbal Medicine, Dahurian Angelica Root or DAR. It is known to cure many ailments including pain, high blood pressure and a number of diseases. This eliminates the complexities of multi herb marketing and focuses the company’s efforts in one unified direction. The one drug focus has a proven record of accomplishment as demonstrated by Ayurvedic. Intelligent marketing and the one drug focus paid off and it now represents a $1billion dollar industry in India alone. China Health Resources is employing this strategy to DAR.

Smart Investors will identify the excellent opportunity here as public awareness for DAR continues to grow. The company sees International markets as representing a $27 billion dollar market and growing. They currently own 40% of the Chinese market share and seek to double the market share through Brand-Building and increasing public awareness. Recently they also received GAP approval equivalent to FDA approval. This allows Global export of DAR, greatly increasing the Market potential as the EU uses GAP standards in agriculture. It is very easy to see the promise of DAR and the excellent opportunity here.

China Health Resources Inc. and its subsidiaries focus on developing and commercializing Dahurian Angelica Root. They are located in the Suining, Sichuan province of China where 70% of China’s DAR output comes from. The company intends to build a total value chain at every step of the DAR Industry, from production to research. The company currently has 11,000-mu DAR field and has built a GAP research basement of 2,000 mu, planting field of 11,000 mu. They also have a number of research agreements with Chinese universities and professors providing a strong platform for R&D. It is traded on the Over-The-Counter exchange under the symbol (CHRI).

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource, Inc. (CHRI.OB) – The Chinese Alternative to the FDA

Friday, February 15th, 2008

When China Health Resources (CHRI) decided to put the bulk of their energy into the development and marketing of Dahurian Angelica Root (which has affectionately become known as “DAR”) It raised some eyebrows. It’s not that often when a very promising company puts most of their eggs in one basket, but yet this is exactly what CHRI did. At first glance this may seem a bit foolhearty, but time has shown us that this was one of the single best moves that a traditional herbal medicine company could make.

DAR has become one of the fastest growing and most demanded herbal remedies in all of China, and in significant portions of India. It’s been shown to help, and even cure in some instances, everything from gum disease, toothache, stomach ache, to blood pressure, migraines and even certain cancers. Yes it’s that important and the Chinese populace had been demanding more and better forms of the herb for years.

Through its subsidiary, Suining Yinfa DAR Industrial Co., Ltd, – China Health Resource, Inc. (CHRI) is committed to developing traditional Chinese herbal medicines. Yet just producing and marketing a high quality DAR product wasn’t enough for China Health, they stepped it up to a whole new level. Working with regulators of the European Union, they helped create a unique category of ranking for Dahurian Angelica Root, and it’s called aptly enough, Good Agricultural Practice or GAP.

GAP takes into account some overriding parameters set forth by the Food and Agriculture Organization of the United Nations. It monitors and measures not only the quality of the product itself (good agricultural product ranking) but of the soil standards, erosion standards, fertilization standards, etc. In layman’s terms, getting a foodstuff certified as “GAP” is almost the equivalent of getting an FDA approval here in the United States.

When China Health helped develop the European Union’s classification for DAR, and was subsequently granted their GAP certificates in the EU, the State regulatory agency in China took note, and accepted it as the benchmark certificate there also. In one fell swoop, CHRI became the defacto “gold standard” of DAR production, and marketing. This is why China Health was indeed willing to put so many eggs in one basket.

Not only did they enjoy the demand of a thousand year culture of herbal remedies in mainland China and the outlier areas such as India, but they also helped set the gold standard for what DAR should be, and then produced their herb to that exacting standard. Talk about a coup!

Attaining state sponsored recognition for an herbal remedy, in which you helped set the parameters of quality, is a mighty accomplishment and one for which we feel CHRI will be rewarded. Here in the states, if you receive FDA approval for a drug, foodstuff, supplement, etc, you can almost guarantee yourself some instant success, as the ranking provides instant credibility. The result in China and the European Union can be expected to be the same.

China health has set some very high standards, which it is achieving daily. By laying the foundation for what DAR production should be in this day and age, it has proven to the world that it is the world class, state of the art producer of DAR, and will indeed reap the rewards of such sigh recognition.

Investors willing to delve into the area of homeopathic and/or herbal medicine and reap the benefits of a 30 billion dollar a year and growing business should take a serious look at CHRI. The GAP ranking they have helped set the standards for, and the certificates they’ve received, can be closely compared to attaining the FDA approval here in the States, and most would agree that the credibility that it brings to the table is usually rewarded in the investment return. It demands a close look.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource, Inc. (CHRI.OB) – All the Right Ingredients

Thursday, February 14th, 2008

If one was to ask the average man in the street where he thought he’d get the best investment returns, almost invariably he’d say “China” and for good reason. For the past 12 years, China’s been growing at a rate above 6%, and in the past 4 years alone , it’s been closer to 12%.Compared to the rather dismal growth rate the US economy has been experiencing, it makes a lot of sense to consider the Chinese alternative.

But history is full of good intentioned ideas that shipwrecked on the way to glory. China is certainly no different. Just because a company is based in China, or has a China based market, or creates and produces in China, it doesn’t necessarily mean that company is going to be a success. History unfortunately, is full of Chinese companies that met the same rocky reef and sank. So then, what makes the difference between a company that makes US Analysts warm and fuzzy, yet crashes on the rocks, versus the Chinese company that succeeds and grows? It’s the culture acceptance.

China is a country wrapped in thousands of years of culture, and what plays well in the US or Europe, may not necessarily play so well there. Attitudes and culture form the basis for homegrown demand in China. So it goes without saying, that the single best idea one could possibly launch is a company that appeals to the wants and desires of Chinese culture, but also finds a niche on the global stage. Satisfy these two situations, and you’ve dialed in the basic ingredients for a very successful company.

China Health Resource Inc has done just that, and could very well be a tremendous investing opportunity. First, let’s discuss who they are, and what they bring to the table. Through its subsidiary, Suining Yinfa DAR Industrial Co., Ltd, China Health Resource, Inc. (CHRI) is committed to developing traditional Chinese herbal medicine and produces, processes and sells one of the major Chinese herbs, Dahurian Angelica Root. This herb is widely used by many to alleviate pain, high blood pressure, cancer and many other illnesses.

At first blush one might think that this is nothing to get very excited about, I mean we’re talking about some “herbal medicine”. But you’d be sadly mistaken. Herbal medicine has been part of the Chinese culture for thousands of years and the standard Chinese apothecary is brimming with traditional herbal cures. So ingrained in the history of China is the natural approach to healing, that its modern medicines that have to fight for “shelf space”.

So, if we look at CHRI as a well accepted Chinese company, we are already in the driver seat. But, what about the rest of the world? This is where CHRI is going to deliver the “two” in the classic “one/two” punch. A movement has been going on for some 30 plus years in the developed countries to explore the more natural homeopathic and herbal approach to curing illness, and the statistics are quite stunning. In the US, where the FDA, and AMA blanket the airwaves with the most modern of medical drug allure, herbal medicine is growing at a brisk 20%+ per annum, and in Europe, where a more natural approach to such things is, well, more natural to them, the growth rate exceeds 30%. Combined, the total dollars spent on herbal related medicines is north of 25 billion dollars per year, and growing at those incredible rates we mentioned.

It’s always been my approach that when dissecting a business to determine if it warrants a closer look, one of the most basic necessities is that there is demand and growth. The natural medicine segment of the healthcare market certainly delivers on that, and with China Health Resource we reap the benefits of the acceptance of the Chinese marketplace. This is paramount, and what will indeed separate the winners from the wannabee’s. When you look at the one billion plus possible consumers in China, the single most important question you can ask is, “will the Chinese buy it”. With herbal medicine, the answer’s already been carved in historical stone. Yes indeed they will.

There is a litany of topics that make China Health an interesting company, and we’ve only discussed one of them here. We’ve settled the “is there any demand” question quite remarkably. We haven’t even touched on their bellwether product called DAR or Dahurian Angelica Root. It is widely accepted that when boiled, and applied in various forms DAR has been shown to cure the common cold, headache, toothache and stomach-ache and is used also used in pain, high blood pressure, and even cancer treatments. We also haven’t touched on the recent blockbuster news that they have received what one could consider the equivalent to a Chinese FDA approval for manufacture and distribution of this popular medicine.

China Health Resource has a lot potential, and we’ve only addressed one avenue of it here. It’s our opinion that you should pull up a chair and take a few minutes to get acquainted with CHRI, it might be one of the best friendships you make in your investing career.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource, Inc. (CHRI.OB) and Subsidiaries Growth Strategy for Banking on Medicinal Chinese Herb

Thursday, February 14th, 2008

Utilizing its subsidiaries such as Suining Yinfa DAR Industrial Co. Ltd, China Health Resource, Inc. (OTCBB: CHRI) produces, processes, and commercializes the widely-used traditional Chinese herb, Dahurian Angelica Root. China Health is based out of the Sichuan province and represents more than 70% of the country’s DAR total output.

The root is considered an integral ingredient in traditional Chinese medicine, and is used to treat pain, high blood pressure, cancer and other ailments. The root is also known to reduce itching and has an energizing aroma thought to awaken the brain.

China Health has signed a letter of intent with Sichuan Zhefeng Medicine Co. to enhance the achievements of the company’s industrial chain plan. According to the plan, Zhefeng will serve as the production base for China Health’s DAR products. From here China Health plans to expand the growing area of the herbal root, develop a Good Manufacture Practice certified process factory, and establish a Good Supplying Practice sales platform.

Through this growth strategy, China Health intends on becoming a key competitive player in the industry, dominating market share and increasing the value of DAR.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource, Inc. (CHRI.OB) Share Price Explodes 63.93% After Releasing News

Wednesday, February 13th, 2008

After announcing that Mr. Jia Minru, a physician and professor of the Chinese Medicine University, joined their team, China Resources’ (CHRI.OB) share price immediately sky rocketed and is currently trading at $.17, 63.93% higher than yesterday’s close.

Mr. Jia Minru will be responsible for deep development, high-tech development, and systematic research of deep processed products of Chuan DAR GAP. He brings 40+ years of research experience in medicine and herb resource development to the company. Previously he was the advisor of the Chinese Medicine Academy, the dean of Chinese Medicine University, the deputy dean of Chinese Medicine Association, director of Chinese Medicine and Herb Committee, and a member of Sichuan New Medicine Assessment Center.

We announced that the Company was a “One to Watch” last week before the recent explosion in volume and price increase. China Health Resources is a leading industrialized agricultural corporation focused on the production and processing of dahurian angelica root, a widely used herb in China known to be a vital ingredient in Chinese traditional medicine.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource Inc. (CHRI.OB) Focused on Medicinal Benefits of Sichuan Angelica

Tuesday, February 12th, 2008

 Through its subsidiary Suining Yinfa DAR Industrial Co., Ltd. (DAR Industrial), the company engages in production, processing, selling and marketing the Chinese herb, Angelica Root. The company says that the herbal medicine market is extremely large, representing $27 billion dollars in the US and the EU. On top of this, the markets are expected to grow at rate of up to 30%.

Many know the root for its medicinal powers. It is used to relieve pain, cure many diseases and lower blood pressure. The company is always investigating new novel uses for their medicinal herbs though intensive research. They are focused on bringing at least four new varieties of Sichuan Angelica to the market every year.

The company was instrumental in implementing a (DAR) standard utilized by European Union countries. This enables the company to participate in Global markets and become an industry leader worldwide. They are located in the Suining province where 70% of National production of the Sichuan Angelica root comes from China. This unique environment and prevalence of technology help ensure that the company’s medicines are GAP certified.

They intend to continue improving production standards and enlarging growing areas that meet GAP standards. A continued effort to produce the highest quality seeds with the lowest amount of defects is the company’s 1# priority. They believe that national marketing campaigns will increase the medicinal medicine market share of Sichuan Angelica by 40%-80%. The company is committed to the further commercialization of the Angelica root and its expansion into the Global marketplace.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resources, Inc. (CHRI.OB) Announces Promotion through QualityStocks.net

Tuesday, February 12th, 2008

China Health Resource, Inc. will be featured in upcoming Daily Newsletters, Daily Blogs, Message Boards, and the Small Cap Daily Internet broadcasts put out by QualityStocks. QualityStocks has over 600,000+ subscribers to The Daily Stock Newsletter, which is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters and puts it all into one Free Daily Newsletter Report.

Ji Guang Wang, President and Director of China Health Resource, has the company focused on producing, processing and selling one of the major Chinese herbs, Dahurian Angelica Root. Mr. Wang stated, “China Health Resource has a unique and solid business foundation, and appreciates the opportunity to sponsor the Quality Stocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

Michael McCarthy, Director of Business Development for QualityStocks.net, stated that his company is pleased to have China Health Resource as a featured company. He continued to say that the Company is methodically establishing itself as a category leader.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resources, Inc. (CHRI.OB) Signs $3 Million Project Agreement with Guangzhou Qingping Market

Monday, February 11th, 2008

Incorporated in 2001, China Health Resources Co., Ltd. (CHRI) has grown to become one of the leading industrialized agricultural corporations in China. The company is engaged in the production and processing of Chinese traditional medicines, such as the widely used Dahurian Angelica Root.

Today the company announced it has secured a project investment contract with Guangzhou Qingping Market to build Herb Network Logistics and a Sales Platform. According to the press release, the companies’ aggregate $3 million investment into the project will expand the herb market of spot trade and futures trade through e-commerce.

In the statement, China Health said it’s technological and natural resources, paired with Qinping’s market advantages, will enhance the competency of the platform. China Health’s current business plan is to distribute DAR products for the treatment of pain, swelling and pustule. China Health attained the Good Agricultural Practice certification, a national compulsory criterion for food and drug industries, for its DAR products and related production technology. This will assist the company in battling harmful micro-organisms to ensure agricultural safety.

The logistics and sales platform project will commence this month, and is expected to be completed in 2009.

Let us hear your thoughts: China Health Resource, Inc. Message Board

China Health Resource, Inc. (CHRI.OB) is “One to Watch”

Friday, February 8th, 2008

Through its subsidiary, Suining Yinfa DAR Industrial Co., Ltd, China Health Resource, Inc. (CHRI.OB) produces, processes and sells one of the major Chinese herbs, Dahurian Angelica Root. The herb is used by many to alleviate pain, high blood pressure, cancer and other illnesses. Dahurian Angelica Root also has applications in cosmetics and chemistry as well.

Suining Yinfa DAR Industrial Co. is committed to developing traditional Chinese herbal medicine and has spent considerable resources Researching and Developing alongside Chengdu University of Traditional Chinese Medicine and Sichuan Provincial Chinese Medicine Research Institute. As a result of their dedicated investment, Dahurian Angelica Root has been used in more medical applications and additional industries.

The market for herbal medicine is rapidly growing on a global basis and the Company believes its herb has great potential to capitalize on the growing trend. The growth rate is currently at 20% each year in the U.S. and 30% in the European Union. China Health Resource, Inc. is focused on standardizing the Traditional Chinese Herbal Medicine and intends to expand into the $27 Billion international herbal medicine market.

Let us hear your thoughts: China Health Resource, Inc. Message Board